cd19-tricar-t
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2018 (NCT03720496)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03910842 | Early Phase 1 (Phase 1) | May 15, 2019 | Central South University, Timmune Biotech Inc. |
| NCT03790891 | Early Phase 1 (Phase 1) | Jan 5, 2019 | Hainan People's Hospital, Timmune Biotech Inc. |
| NCT03720496 | Phase 1 | Nov 1, 2018 | Hainan Medical College, Timmune Biotech Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Timmune Biotech Inc. | For profit | 3 | 3 | 1 | 2018 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Hainan Medical College | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Hainan People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1